Hematology Frontier

The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology.Highlights included innovative therapies for blood cancers, breakthroughs in stem…

From July 5th to 7th, the 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) were grandly held in Guangzhou. The conference gathered domestic oncology experts and related professionals to witness the past year's research progress in clinical oncology in China and discuss the future innovative development path of clinical oncology in China. "Oncology Frontier - Hematology Frontier" invited renowned expert in the field of hematologic oncology, Professor Zhixiang Shen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, for an interview. He introduced major research advancements in hematologic oncology and shared his profound insights on innovation translation and the importance of integrating innovative results into clinical practice.

European Hematology Association (EHA) 2024 has been an incredible journey! Thank you to all the amazing professionals who made it unforgettable. hashtag#EHA2024 hashtag#Hematology hashtag#ConferenceHighlights hashtag#Research

Published on November 5, 2024, in Blood, the double-blind, placebo-controlled PIVOT trial offers new insights into hydroxyurea for HbSC disease, where treatment guidelines remain unclear. Conducted at Korle Bu Teaching…

In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.

The curtains have closed on another enlightening EHA Congress, a beacon of innovation in hematology. This year's gathering was a testament to the relentless pursuit of medical advancement, with a…

On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let's take a moment to appreciate their unwavering commitment to preserving…

In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…

Introduction: In this era of information explosion, how can one quickly access the latest developments in the field? Here, we select the latest literature in the field every month, focusing…

In the field of myelofibrosis treatment, allogeneic hematopoietic stem cell transplantation (allo-HSCT) serves as a curative approach, and the optimization of related strategies is particularly crucial. Recently, at the 12th…